Warning: The NCBI web site requires JavaScript to function. more...
Cohort study of the association of antibody levels to AMA1, MSP119, MSP3 and GLURP with protection from clinical malaria in Ghanaian children.
Dodoo D, Aikins A, Kusi KA, Lamptey H, Remarque E, Milligan P, Bosomprah S, Chilengi R, Osei YD, Akanmori BD, Theisen M.
Malar J. 2008 Jul 29;7:142.
Related citations
Humoral responses to Plasmodium falciparum blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa.
Nebie I, Diarra A, Ouedraogo A, Soulama I, Bougouma EC, Tiono AB, Konate AT, Chilengi R, Theisen M, Dodoo D, Remarque E, Bosomprah S, Milligan P, Sirima SB.
Infect Immun. 2008 Feb;76(2):759-66. Epub 2007 Dec 10.
Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness.
Stanisic DI, Richards JS, McCallum FJ, Michon P, King CL, Schoepflin S, Gilson PR, Murphy VJ, Anders RF, Mueller I, Beeson JG.
Infect Immun. 2009 Mar;77(3):1165-74. Epub 2009 Jan 12.
Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein.
Soe S, Theisen M, Roussilhon C, Aye KS, Druilhe P.
Infect Immun. 2004 Jan;72(1):247-52.
The quantity and quality of African children's IgG responses to merozoite surface antigens reflect protection against Plasmodium falciparum malaria.
Courtin D, Oesterholt M, Huismans H, Kusi K, Milet J, Badaut C, Gaye O, Roeffen W, Remarque EJ, Sauerwein R, Garcia A, Luty AJ.
PLoS One. 2009 Oct 27;4(10):e7590.
Acquisition of antibodies to merozoite surface protein 3 among residents of Korogwe, north eastern Tanzania.
Segeja MD, Mmbando BP, Seth MD, Lusingu JP, Lemnge MM.
BMC Infect Dis. 2010 Mar 8;10:55.
Anti-malaria humoral responses in children exposed to Plasmodium falciparum and Schistosoma haematobium.
Mutapi F, Roussilhon C, Mduluza T, Druilhe P.
Mem Inst Oswaldo Cruz. 2007 Jun;102(3):405-9.
Do antibody responses to malaria vaccine candidates influenced by the level of malaria transmission protect from malaria?
Nebie I, Tiono AB, Diallo DA, Samandoulougou S, Diarra A, Konate AT, Cuzin-Ouattara N, Theisen M, Corradin G, Cousens S, Ouattara AS, Ilboudo-Sanogo E, Sirima BS.
Trop Med Int Health. 2008 Feb;13(2):229-37.
Levels of antibody to conserved parts of Plasmodium falciparum merozoite surface protein 1 in Ghanaian children are not associated with protection from clinical malaria.
Dodoo D, Theander TG, Kurtzhals JA, Koram K, Riley E, Akanmori BD, Nkrumah FK, Hviid L.
Infect Immun. 1999 May;67(5):2131-7.
Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12-24 months.
Lusingu JP, Gesase S, Msham S, Francis F, Lemnge M, Seth M, Sembuche S, Rutta A, Minja D, Segeja MD, Bosomprah S, Cousens S, Noor R, Chilengi R, Druilhe P.
Malar J. 2009 Jul 17;8:163.
Immunoglobulin G antibodies to merozoite surface antigens are associated with recovery from chloroquine-resistant Plasmodium falciparum in Gambian children.
Pinder M, Sutherland CJ, Sisay-Joof F, Ismaili J, McCall MB, Ord R, Hallett R, Holder AA, Milligan P.
Infect Immun. 2006 May;74(5):2887-93.
Variation in the relationship between anti-MSP-1(19) antibody response and age in children infected with Plasmodium falciparum during the dry and rainy seasons.
Omosun YO, Anumudu CI, Adoro S, Odaibo AB, Sodeinde O, Holder AA, Nwagwu M, Nwuba RI.
Acta Trop. 2005 Sep;95(3):233-47.
Naturally acquired antibodies to polymorphic and conserved epitopes of Plasmodium falciparum merozoite surface protein 3.
Osier FH, Polley SD, Mwangi T, Lowe B, Conway DJ, Marsh K.
Parasite Immunol. 2007 Aug;29(8):387-94.
Correlations between treatment outcome and both anti-MSP119 antibody response and erythrocyte-related genetic factors in Plasmodium falciparum malaria.
Aubouy A, Migot-Nabias F, Deloron P.
Infect Genet Evol. 2007 Mar;7(2):147-54. Epub 2006 Aug 4.
Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3.
Roussilhon C, Oeuvray C, Müller-Graf C, Tall A, Rogier C, Trape JF, Theisen M, Balde A, Pérignon JL, Druilhe P.
PLoS Med. 2007 Nov 13;4(11):e320.
Human leukocyte antigen class II alleles influence levels of antibodies to the Plasmodium falciparum asexual-stage apical membrane antigen 1 but not to merozoite surface antigen 2 and merozoite surface protein 1.
Johnson AH, Leke RG, Mendell NR, Shon D, Suh YJ, Bomba-Nkolo D, Tchinda V, Kouontchou S, Thuita LW, van der Wel AM, Thomas A, Stowers A, Saul A, Zhou A, Taylor DW, Quakyi IA.
Infect Immun. 2004 May;72(5):2762-71.
IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria.
Taylor RR, Allen SJ, Greenwood BM, Riley EM.
Am J Trop Med Hyg. 1998 Apr;58(4):406-13.
Acquisition of antibody isotypes against Plasmodium falciparum blood stage antigens in a birth cohort.
Duah NO, Miles DJ, Whittle HC, Conway DJ.
Parasite Immunol. 2010 Feb;32(2):125-34.
High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya.
Polley SD, Conway DJ, Cavanagh DR, McBride JS, Lowe BS, Williams TN, Mwangi TW, Marsh K.
Vaccine. 2006 May 8;24(19):4233-46. Epub 2005 Jul 27.
Prediction of merozoite surface protein 1 and apical membrane antigen 1 vaccine efficacies against Plasmodium chabaudi malaria based on prechallenge antibody responses.
Lynch MM, Cernetich-Ott A, Weidanz WP, Burns JM Jr.
Clin Vaccine Immunol. 2009 Mar;16(3):293-302. Epub 2008 Dec 30.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on